Alaunos Therapeutics (TCRT) Stifel 2026 Healthcare Conference 2026 summary

Pipeline and clinical plans

• VLR199 is designed to mimic sotatercept’s activin mechanism; Phase I entry is planned for 2027, with dose-dependent serum FSH and other biomarkers guiding Phase II dose selection.

• Phase II studies are planned in PAH, HFpEF and lung diseases; the speaker described compact PAH studies of 100–150 patients and a clear Phase III path using six-minute walk distance.

• VLR247 and VLR258 are next-generation approaches designed to spare BMP9/10; plans depend partly on upcoming GSK data, with VLR199 proceeding as planned if those results are negative.

• VLR360, a half-life-extended anti-PDGFB antibody, is planned for clinic entry in 2027; VLR199 and VLR360 proof-of-concept data are targeted for 2028, with a co-formulated PAH combination also envisioned.

Target markets and competitive landscape

• Management cited sotatercept sales of $2B two years after launch and estimated $8B–$10B peak potential in PAH, a market of 30,000–50,000 patients.

• HFpEF has roughly 10 times the potential patient population of PAH; Merck’s Phase II result showed a 0.18 hazard ratio at 0.3 mg/kg, while the 0.7 mg/kg dose looked worse, and Phase III is advancing at the lower dose.

• The strategy targets pulmonary hypertension associated with HFpEF and group-three lung diseases, including ILD, IPF, PPF and COPD; cited ILD prevalence was 60,000–70,000 patients, with other indications larger.

• The speaker pointed to physician case reports of activin-drug use in group-three disease, with reported improvements in six-minute walk distance, PVR and BNP; these uses are not yet formal clinical evidence.

Differentiation and execution

• Potential improvements over sotatercept include dose optimization, delivery and convenience; the speaker said a likely goal could be simpler weight-band dosing, potentially with a subcutaneous auto-injector.

• The speaker attributed earlier Keros setbacks to a molecule that spared activin along with BMP9/10, requiring higher dosing to achieve similar activin inhibition; the strategy is to advance both BMP9/10-sparing assets and VLR199.

• PAH treatment is a polypharmacy setting, and management sees potential for both switching and adding mechanisms; a focused specialist prescriber base could support rapid uptake if data are compelling.

• The $200M financing target was increased to $350M on demand, extending runway into 2029; a permanent CEO is expected within the first year, with the current president moving to the board.